Justin Byers

Axio BioPharma is a Contract Development and Manufacturing Organization (CDMO) transforming biopharmaceutical manufacturing. We accelerate the development of mammalian-expressed recombinant proteins, with a focus on monoclonal antibodies (mAbs). Our approach significantly reduces the timeline from lab research to clinical manufacturing, enabling faster delivery of critical therapies. At Axio BioPharma, we are committed to reducing the time it takes to get life-saving therapies to patients.